跳转至内容
Merck
CN

主要文件

查看所有文档

M5255

霉酚酸

from Penicillium brevicompactum, ≥98% (HPLC), powder, IMP dehydrogenase inhibitor

别名:

6-（1,3-二氢-7-羟基-5-甲氧基-4-甲基-1-氧代异苯并呋喃-6-基）-4-甲基-4-己酸, 6-（4-羟基-6-甲氧基-7-甲基-3-氧代-5-酞酰）-4-甲基-4-己烯酸, NSC 129185

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C17H20O6
化学文摘社编号:
24280-93-1
分子量:
320.34
NACRES:
NA.77
PubChem Substance ID:
24896987
UNSPSC Code:
12352106
EC Number:
246-119-3
MDL number:
MFCD00036814
Beilstein/REAXYS Number:
1295848
Assay:
≥98%
Quality level:
300
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

霉酚酸, ≥98%

biological source

Penicillium brevicompactum

Quality Level

300

assay

≥98%

color

white to yellow-white

mp

<143.0 °C

solubility

methanol: 49.00-51.00 mg/mL, clear, colorless to faintly yellow

mode of action

enzyme | inhibits

originator

Novartis

storage temp.

2-8°C

SMILES string

COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O

InChI

1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+

InChI key

HPNSFSBZBAHARI-RUDMXATFSA-N

Gene Information

human ... IMPDH1(3614), IMPDH2(3615)

Application

霉酚酸 (MPA) 由 青霉 (Penicillum brevi-compactum) 产生 ，是一种选择性的肌苷一磷酸脱氢酶抑制剂，从而抑制 T、B 淋巴细胞的 DNA 合成。在人淋巴和单核细胞系中，它还被证明可作为免疫抑制剂，以及单核细胞分化和凋亡的诱导剂。作为选择剂，MPA 用于表达大肠杆菌黄嘌呤-鸟嘌呤磷酸核糖转移酶基因的转染动物细胞，推荐使用 25μg/mL。

Biochem/physiol Actions

作用方式：本品通过抑制细胞因子诱导的一氧化氮生成，抑制嘌呤核苷酸的早期生物合成，并作为 IMP 脱氢酶的特异性抑制剂发挥作用。

Features and Benefits

该化合物由 Novartis 开发。要浏览其他制药公司开发的化合物列表批准的药物/候选药物的列表，请 点击这里 。

Preparation Note

麦考酚酸可溶于 50 mg/mL 甲醇，产生无色至淡黄色溶液，以及氯仿、二氯甲烷、乙醇和 1 N 氢氧化钠溶液。复溶后，建议通过 0.22 μm 过滤器灭菌m 孔径过滤器，分装，-20°C 冷冻。

Disclaimer

供应后，本品应在 2-8°C 干燥条件下储存，适当储存时可保持稳定 5 年。

Still not finding the right product?

Explore all of our products under 霉酚酸

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Muta. 2 - Repr. 1B - STOT RE 1 Oral

target_organs

Immune system

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

法规信息

新产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
039M4048V
019M4082V
038M4052V
097M4016V
14161108

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

相关内容

Hylke de Jonge et al.
Therapeutic drug monitoring, 31(4), 416-435 (2009-06-19)
Although therapeutic drug monitoring (TDM) of immunosuppressive drugs has been an integral part of routine clinical practice in solid organ transplantation for many years, ongoing research in the field of immunosuppressive drug metabolism, pharmacokinetics, pharmacogenetics, pharmacodynamics, and clinical TDM keeps
Christine E Staatz et al.
Clinical pharmacokinetics, 50(12), 759-772 (2011-11-18)
This review seeks to summarize the available data about Bayesian estimation of area under the plasma concentration-time curve (AUC) and dosage prediction for mycophenolic acid (MPA) and evaluate whether sufficient evidence is available for routine use of Bayesian dosage prediction
Dirk R J Kuypers et al.
Clinical journal of the American Society of Nephrology : CJASN, 5(2), 341-358 (2010-01-09)
With the increasing use of mycophenolic acid (MPA) in solid organ transplantation, the need for more accurate drug dosing has become evident. Personalized immunosuppressive therapy requires better strategies for avoidance of drug-related toxicity while maintaining efficacy. Few studies have assessed
查看所有相关文献

全球贸易项目编号

货号GTIN
M5255-250MG04061834059615
M5255-50MG04061834059622